Skip to content

Celcuity CELC Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.4B+1,370%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Celcuity's convertible preferred stock outstanding shares?
Celcuity (CELC) reported convertible preferred stock outstanding shares of 0 in Q1 2026.
How has Celcuity's convertible preferred stock outstanding shares changed year-over-year?
Celcuity's convertible preferred stock outstanding shares decreased by 100.0% year-over-year, from 317.6K to 0.
What does convertible preferred stock outstanding shares mean?
This reflects the total number of preferred equity shares currently held by investors that possess the right to be converted into common stock. It is a critical metric for calculating fully diluted share counts and understanding the potential impact of equity conversion on ownership structure.